MIST
NASDAQMilestone Pharmaceuticals Inc.
News · 26 weeks36+100%
2026-03-012026-08-23
Mix1690d
- Insider7(44%)
- SEC Filings3(19%)
- Other3(19%)
- Earnings2(13%)
- Analyst1(6%)
Latest news
25 items- PRMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose Reduced Ventricular Rate and Improved Both Symptom Relief and Treatment Satisfaction in AFib-RVR Population MONTREAL and CHARLOTTE, N.C., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the first patient has been enrolled in the Phase 3 ReVeRA-301 pivotal trial evaluating etripamil for atrial fibrillation with rapid ventric
- ANALYSTCantor Fitzgerald initiated coverage on Milestone Pharmaceuticals with a new price targetCantor Fitzgerald initiated coverage of Milestone Pharmaceuticals with a rating of Overweight and set a new price target of $3.00
- SECMilestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateOver 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray Phase 3 registrational trial of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) first clinical sites activated, advancing Milestone’s potential, second cardiovascular indication $170.6 million in cash, cash equivalents and short-term investments as of June 30, 2026, provides runway into H2 2027 Company to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the d
- SECSEC Form 10-Q filed by Milestone Pharmaceuticals Inc.10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. To access the live conference call, participants may register here. Conference Details: Conference Date:Wednesday, August 12, 2026Conference Time:8:30am ETConference Dial-in:1-877-407-0792Interna
- PRMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the "Options") to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the "Plan"), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees. The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which is equal to the closing price of Milestone’s common shares on the grant date. The shares subjec
- PRAlpha Cognition Announces Election of Dr. Robert Wills as Chairman of the BoardAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. "On behalf of the entire Board of Directors, we are pleased that Dr. Wills will serve as Chairman at this important time for Alpha Cognition," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "He brings a wealth of experience, strategic insight, and a deep understanding of our busi
- SECMilestone Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- INSIDERSEC Form 4 filed by Director Wills Robert James4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Duty Stuart4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Papa Joseph C4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Saik Andrew4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Fischer Seth H. Z.4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Giles Lisa M.4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Tomsicek Michael John4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- SECSEC Form EFFECT filed by Milestone Pharmaceuticals Inc.EFFECT - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York. A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET. The webcast is available to watch both live and replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you
- SECSEC Form S-3 filed by Milestone Pharmaceuticals Inc.S-3 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- SECMilestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate UpdateCARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company makes progress toward broad patient accessAtrial Fibrillation-RVR Phase 3 registration trial initiated: patient enrollment to begin in H2 2026Strong balance sheet of $184.2M provides runway into H2 2027 to fund commercial and operational prioritiesCompany to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of
- SECSEC Form 10-Q filed by Milestone Pharmaceuticals Inc.10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter ended March 31, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Date:Wednesday, May 13, 2026Conference Time:8:30am ETConference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13760062Webcast link:Click here. Participants can use Guest
- SECSEC Form DEFA14A filed by Milestone Pharmaceuticals Inc.DEFA14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- SECSEC Form DEF 14A filed by Milestone Pharmaceuticals Inc.DEF 14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
MIST FAQ
7 questionsWhat does Milestone Pharmaceuticals Inc. do?
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and...Where does MIST stock trade?
Milestone Pharmaceuticals Inc. (MIST) is listed on NASDAQ.What sector and industry is MIST in?
Milestone Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Milestone Pharmaceuticals Inc. go public?
Milestone Pharmaceuticals Inc. (MIST) completed its IPO in 2019.What are analysts saying about MIST?
Milestone Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $300.00 price target on 2026-08-20. Recent price targets range from $300.00 to $1000.00.What companies are similar to MIST?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MIST side-by-side with any of them on Quantisnow.How can I track MIST on Quantisnow?
Quantisnow aggregates Milestone Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIST to receive live email and push alerts on every new disclosure.